BLTE Earnings Prediction
The chart below shows how BLTE performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BLTE sees a -0.97% change in stock price 10 days leading up to the earnings, and a +4.03% change 10 days following the report. On the earnings day itself, the stock moves by -0.33%. This data can give you a slight idea of what to expect for the next quarter's release.
BLTE Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.28
-30.00%
-9.68%
No Data Available
BLTE Earnings Analysis
Belite Bio, Inc American Depositary Shares Corporation (BLTE.O) Earnings Conference Call
Positive
R&D Expense Reduction: R&D expenses decreased to $6.8 million compared to $8.7 million for the same period in 2023, indicating effective cost management.
G&A Expense Increase: G&A expenses increased to $2.9 million compared to $2.2 million for the same period in 2023, primarily due to an increase in share-based compensation, reflecting investment in talent.
Net Loss Improvement: Net loss improved to $8.7 million in Q3 2024 compared to $10.9 million for the same period in 2023, showing progress in financial performance.
Financial Stability Assurance: The company maintains a strong balance sheet with $109 million in cash, ensuring financial stability for ongoing operations and investments.
Clinical Trial Progress: The DRAGON 2 trial continues to progress rapidly with 104 patients fully enrolled, demonstrating strong momentum in clinical development.
Negative
R&D Expense Reduction: R&D expenses decreased to $6.8 million compared to $8.7 million for the same period in 2023, primarily due to fewer CRO milestone payments related to the DRAGON trial.
G&A Expense Increase: G&A expenses increased to $2.9 million compared to $2.2 million for the same period in 2023, primarily due to an increase in share-based compensation granted in Q3 of 2024.
Net Loss Comparison: Net loss was $8.7 million in Q3 2024 compared to $10.9 million for the same period in 2023.
Cash Reserves Decline: The company continues to maintain a strong balance sheet with total cash of $109 million, but this reflects a decrease in cash reserves compared to previous quarters.
Cash Runway and Financial Strain: The company expects a cash runway of about four years to execute all key milestones, indicating potential financial strain if milestones are not met.
BLTE FAQs
How does BLTE typically perform around its earnings report dates?
Is Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BLTE Earning Call Sentiment
Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
BLTE.O
1.13%Positive
The earnings call reveals strong financial health with a $109 million cash position, reduced R&D expenses, and decreased net loss year-over-year. The company has significant regulatory designations and fully enrolled trials, indicating progress. The Q&A highlighted manageable adverse effects and strategic trial execution, boosting confidence. Despite some risks, the overall outlook is optimistic, especially given the market cap, leading to a prediction of a positive stock price movement in the short term.
